Thelansis

Coronary Heart Disease (CHD) Market Outlook Thelansis’s “Coronary Heart Disease (CHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Coronary Heart Disease (CHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the ...

  Coronary Heart Disease (CHD) Market Outlook Thelansis’s “Coronary Heart Disease (CHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Coronary Heart Disease (CHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Coronary Heart Disease (CHD) Overview Coronary heart disease (CHD) stands as the leading global cause of mortality, particularly escalating with age and displaying higher age-adjusted rates in men compared to women. Factors contributing to coronary risks encompass socioeconomic elements, traditional risk factors like hypertension and diabetes, lifestyle choices, and familial predisposition. Various triggers, including ...